Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Science
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Find Cricket Statistics
Hindi
More
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Science
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / India News / Phase I trial results show COVAXIN has tolerable safety: Study
  • India

    Phase I trial results show COVAXIN has tolerable safety: Study

    Written by
    Srijita Sen
    (Sourced from PTI)
    Edited by
    Anamica Singh
    Last updated on Jan 22, 2021, 04:46 pm
    Phase I trial results show COVAXIN has tolerable safety: Study
  • India's indigenous vaccine, COVAXIN, showed enhanced immune response without any serious side effects in the participants enrolled for Phase I trials, according to the results published in The Lancet Infectious Disease journal.

    Developed by Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology, Pune, the vaccine has been granted emergency use authorization in clinical trial mode.

  • In this article
    COVAXIN had raised concerns among experts over its emergency approval No new data available to demonstrate further safety When and where was the Phase I trial carried? What side affects were recorded after the vaccine was administered? How does COVAXIN work? India is also manufacturing Covishield, Oxford-AstraZeneca's coronavirus vaccine
  • Context

    COVAXIN had raised concerns among experts over its emergency approval

  • COVAXIN, which is now undergoing Phase III trials, had raised concerns among experts over its emergency approval earlier this month by India's drug regulator.

    The vaccine, codenamed BBV152, was well tolerated in all dose groups with no vaccine-related serious adverse events, noted the authors of the study funded by Bharat Biotech.

    The same results were earlier published in the pre-print server medRxiv in December.

  • Details

    No new data available to demonstrate further safety

    No new data available to demonstrate further safety
  • However, there has been no new data released in the public domain which could demonstrate further safety and efficacy of the preventive.

    The authors said that all adverse events were mild and moderate, and were more frequent after the first dose, adding that one adverse event was reported but was unrelated to the vaccine.

  • Background

    When and where was the Phase I trial carried?

    When and where was the Phase I trial carried?
  • The randomized Phase I trial was carried at 11 hospitals across India.

    Adults aged 18-55 years who were deemed healthy by the investigator were eligible.

    Between July 13 and 30, 2020, 827 participants were screened, of whom 375 were enrolled.

    Among the enrolled participants, 100 each were randomly assigned to the three vaccine groups, and 75 were randomly assigned to the control group.

  • Outcomes

    What side affects were recorded after the vaccine was administered?

  • Two intramuscular doses of vaccines were administered 14 days apart.

    "BBV152 led to tolerable safety outcomes and enhanced immune responses. The vaccine was well tolerated in all dose groups with no vaccine-related serious adverse events," the authors of the study said.

    The most common adverse event was pain at the injection site, followed by headache, fatigue, and fever.

  • Information

    How does COVAXIN work?

  • COVAXIN is an inactivated vaccine developed by chemically treating novel coronavirus samples to make them incapable of reproduction. This process leaves the viral proteins, including the spike protein of the coronavirus which it uses to enter the human cells, intact.

  • Vaccines

    India is also manufacturing Covishield, Oxford-AstraZeneca's coronavirus vaccine

    India is also manufacturing Covishield, Oxford-AstraZeneca's coronavirus vaccine
  • Given as two doses, three weeks apart, the viral proteins in the vaccine activate the immune system and prepare people for future infections with the actual infectious virus.

    According to Bharat Biotech, the therapeutic can be stored at room temperature for at least a week.

    Apart from COVAXIN, the Serum Institute of India is manufacturing the other vaccine, Covishield, Oxford-AstraZeneca's coronavirus vaccine.

  • Vaccine
  • COVAXIN
  •  
Latest News
  • Coronavirus: India's tally reaches 11.04 million with 17K+ new cases
    Coronavirus: India's tally reaches 11.04 million with 17K+ new cases
    India
  • NewsBytes Briefing: Apple M1 Macs are dying slowly, and more
    NewsBytes Briefing: Apple M1 Macs are dying slowly, and more
    Science
  • Barack Obama, Bruce Springsteen team up with Spotify for podcast
    Barack Obama, Bruce Springsteen team up with Spotify for podcast
    Entertainment
  • Mi 11 Lite appears in live images, features detailed
    Mi 11 Lite appears in live images, features detailed
    Science
  • Nissan Magnite garners 40,000 bookings in India; production ramped up
    Nissan Magnite garners 40,000 bookings in India; production ramped up
    Auto
Related Timelines
  • SII, Bharat Biotech ensure 'smooth roll out' of vaccines globally
    SII, Bharat Biotech ensure 'smooth roll out' of vaccines globally
    India
  • SII's Covishield, Bharat Biotech's COVAXIN granted emergency approval, says DCGI
    SII's Covishield, Bharat Biotech's COVAXIN granted emergency approval, says DCGI
    India
  • India could start 2021 with COVID-19 vaccine in hand: DCGI
    India could start 2021 with COVID-19 vaccine in hand: DCGI
    India
  • Coronavirus: 'Davai bhi, kadaai bhi,' Modi calls for sustained caution
    Coronavirus: 'Davai bhi, kadaai bhi,' Modi calls for sustained caution
    India
Trending Topics
ISRO Vaccine Farmers Protest Uttarakhand Glacier Disaster Toolkit Case
Next News Article
Share
Cancel

Want to share it with your friends too?

Facebook Whatsapp Twitter Linkedin
Copied

Love India news?

Subscribe to stay updated.

India Thumbnail
India News Business News World News Politics News Sports News Science News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Bharti Airtel Mukesh Ambani Indian Premier League Samsung Virat Kohli Rohit Sharma
Cricket News Facebook YouTube Hollywood News WhatsApp Netflix Bollywood News ISRO Spotify Yoga
Honda Batman Football News BMW Vaccine Reliance Jio OPPO Food News, Healthy Recipes Royal Challengers Bangalore Toyota
Fashion Tips Ishant Sharma Farmers Protest Mercedes Isha Ambani India Vs England Cricket OnePlus Mobiles Android TV Smart TV Robert Lewandowski
Marvel Comics Avengers Neha Kakkar Mena Massoud
About Us Privacy Policy Terms & Conditions Contact Us News Reviews News Archive Topics Archive Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2021